TAmiRNA GmbH was founded in 2013 with the mission to develop diagnostic solutions for unmet clinical needs and to offer biomarker contract research services in compliance with the high standards required by diagnostics development. TAmiRNA´s R&D pipeline includes projects in the area of osteoporosis (osteomiR™), cardiovascular disease (thrombomiR®), senescence-associated diseases (senomiR®) and liver diseases (hepatomiR®). In addition, TAmiRNA supports R&D teams at universities and companies with RNA biomarkers solutions for pre-clinical and clinical drug safety research (toxomiR®) and provides compelling solutions for the analysis of non-coding RNAs in biofluids, single-cells or tissue compartments in any research area.